Alexion Pharmaceuticals, Inc. (ALXN) insiders have most recently took part in a trading activity. On Jun 15, 2017 Baker Bros. Advisors Lp, Director bought 660,779 shares having total worth of $77,529,200 at the price of $117.33 per share, following the transaction a total of 1,140,709 shares owned by Baker Bros. Advisors Lp. Before this latest buy, Baker Bros. Advisors Lp purchased ALXN at 1 other times during the past twelve months, for a total investment of $1569.1M at an average of $116.32 per share.
On Jun 14, 2017 Baker Bros. Advisors Lp, Director bought 1,348,955 shares having total worth of $156,910,446 at the price of $116.32 per share, following the transaction a total of 7,478,469 shares owned by Baker Bros. Advisors Lp.
Furthermore, over the past 12 months , the stock was traded 45 times by insiders. In 45 of these trades, the insider was a seller .
Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded up 9.26% on Jun 14, 2017, hitting $118. 10,327,847 shares of the company’s stock traded hands. Alexion Pharmaceuticals, Inc. has a 52 week low of $97.7 and a 52 week high of $184.9. The company’s market cap is $28,250 million.
Alexion Pharmaceuticals, Inc. (ALXN) last announced its earnings results on Apr 27, 2017. The company reported 1.38 earnings per share (EPS) for the quarter, higher than the consensus estimate of 1.24 by $0.14. The company had revenue of $870 million for the quarter, compared to the consensus estimate of $825 million. During the same quarter in the previous year, the company posted 1.11 earnings per share. The company’s revenue for the quarter was up 24% on a year-over-year basis.
|earnings per share||1.38||1.26||1.23||1.13||1.11||1.13||1.16||1.44||1.28||1.30|
Alexion Pharmaceuticals, Inc. is a Delaware based company incorporated in 1992 is a biopharmaceutical company serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria, an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome, an ultra-rare and life-threatening genetic disease. The Company also evaluating other potential indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism. Soliris is designed to inhibit a specific aspect of the complement component of the immune system and thereby treat inflammation associated with chronic disorders in the therapeutic areas of hematology, nephrology, transplant rejection, neurology and ophthalmology. Soliris is a humanized monoclonal antibody that blocks terminal complement activity at the doses currently prescribed. Soliris was approved for the treatment of PNH by the U.S. Food and Drug Administration (FDA) and the European Commission (EC) in 2007 and by Japan’s Ministry of Health, Labour and Welfare (MHLW) in 2010, and has been approved in several other territories. The Company competes with large pharmaceutical companies that produce and market synthetic compounds and with specialized biotechnology firms in the United States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018